<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01673373</url>
  </required_header>
  <id_info>
    <org_study_id>iCAST™ RX-ARAS-001</org_study_id>
    <nct_id>NCT01673373</nct_id>
  </id_info>
  <brief_title>Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension</brief_title>
  <acronym>ARTISAN</acronym>
  <official_title>ARTISAN: iCAST™ RX De Novo Stent Placement for the Treatment of Atherosclerotic Renal Artery Stenosis in Patients With Resistant Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrium Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atrium Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to test how well the iCAST™ RX Stent works in patients diagnosed
      with atherosclerotic renal artery stenosis and whether or not increased blood flow by the
      stent will help to control blood pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-arm, multicenter clinical trial that will take place at up to
      25 US/ Outside US (OUS) sites. Primary endpoints have been determined to show the safety,
      effectiveness, and clinical outcomes of the iCAST™ RX Stent System. Safety and effectiveness
      will be evaluated based on the primary patency rate at 9-months on a per lesion basis
      evaluated against a performance goal of published studies with bare-metal stents. The primary
      clinical endpoint will assess the improvement in Systolic Blood Pressure (SBP) at 9-months as
      compared to baseline Systolic Blood Pressure.

      Eligible subjects will undergo a two-week Medical Documentation Screening period to confirm
      resistant hypertension (SBP ≥ 155mmHg) while on maximum tolerable doses of ≥ three
      anti-hypertensive medications from at least three distinct classes of drugs, one of which
      must be a diuretic.

      There must be documented clinical evidence to support likelihood of angiographic findings &gt;
      80% whether it is Duplex Ultrasound (DUS), Computed Tomography angiogram (CTa), Magnetic
      Resonance angiogram (MRa) or other medical evidence. After meeting screening and clinical
      eligibility criteria, subjects will undergo a baseline assessment for angiographic
      eligibility. After angiographic documentation of a ≥ 80% renal artery stenosis or Fraction
      Flow Reserve (FFR) &lt; 0.8 is confirmed, the subject may be enrolled in the trial by placement
      of the investigational device.

      The 9-month visit will include a follow-up DUS of the target renal artery. If the DUS is
      non-diagnostic due to an imaging problem, such as overlying bowel gas or body habitus, a
      second DUS may be attempted. If the DUS is indicative of ≥ 60% stenosis as determined by the
      core laboratory, or the second DUS remains non-diagnostic, a contrast angiogram will be used
      to assess the degree of restenosis of the covered stent(s).

      Clinical follow-up visits will be required for all enrolled subjects at 30-days, 9-months,
      12-months, 24-months, and 36-months. A 6-month and 18-month visit will occur via telephone to
      collect medication usage and Adverse Events (AEs) only. The 36-month clinic office visit will
      be required as the final safety visit.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 23, 2012</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">June 27, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency</measure>
    <time_frame>9 months</time_frame>
    <description>Primary patency rate at 9 months was defined as continuous patency without the occurrence of a total occlusion of the original lesion, without a re-intervention to treat a partial or total occlusion of the stented segment, or bypass of the stented segment due to clinically-driven restenosis or occlusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>Baseline and 9 months</time_frame>
    <description>Change in systolic blood pressure (SBP) at 9 months as compared to baseline SBP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure-Related Major Adverse Events (MAE)</measure>
    <time_frame>30 days, 9 months</time_frame>
    <description>The occurence of procedure-related MAEs is reported as a percentage of subjects with MAE. Inclusive of:
Procedure- or device-related occurrence of death
Q-Wave myocardial infarction (MI)
Clinically driven target lesion revascularization (TLR)
Significant embolic events defined as unanticipated kidney/bowel infarct, clinically driven by symptoms of abdominal or back pain and confirmed with CT scan or open surgery; lower extremity ulceration or gangrene; or kidney failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical Success</measure>
    <time_frame>Day of Procedure</time_frame>
    <description>Technical success is defined as successful delivery and deployment of the iCAST™ RX Stent System with ≤ 30% residual angiographic stenosis after covered stent deployment (including post-dilatation) assessed via quantitative vascular analysis (QVA) by an independent core laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Procedural Success</measure>
    <time_frame>Day of Procedure, prior to hospital discharge</time_frame>
    <description>Acute procedural success is defined as technical success without the occurrence of MAE prior to hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>9 months</time_frame>
    <description>Target Lesion Revascularization (TLR) is measured as the proportion of subjects-lesions that require a clinically-driven reintervention of the target lesion through 9 months.
a. A clinically-driven TLR is defined as a TLR (percutaneous balloon angioplasty (PTA), bare metal stent or repeat covered stent deployment, or surgical bypass) due to documented recurrent hypertension from 30-days post-procedure level and/or deterioration in renal function from baseline value, associated with angiographic core laboratory adjudication of a ≥ 60% diameter covered stent restenosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Incidental TLR</measure>
    <time_frame>9 months</time_frame>
    <description>The rate of incidental TLR is the rate of TLRs not meeting the definition of a clinically-driven TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure (SBP) Control</measure>
    <time_frame>Baseline and 30 days</time_frame>
    <description>The change in SBP from baseline to 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBP Control</measure>
    <time_frame>Baseline and 9 months</time_frame>
    <description>The change in SBP from baseline to 9 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Patency Rate</measure>
    <time_frame>9 months</time_frame>
    <description>Secondary patency rate at 9 months after a clinically-driven TLR which restores patency after total occlusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Anti-Hypertensive Medications</measure>
    <time_frame>Baseline and 9 months</time_frame>
    <description>Change in number of anti-hypertensive medications as compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Renal Function</measure>
    <time_frame>Baseline and 30 days</time_frame>
    <description>Renal function compared to baseline as measured by estimated Glomerular Filtration Rate (eGFR) at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Renal Function</measure>
    <time_frame>Baseline and 9 months</time_frame>
    <description>Renal function compared to baseline as measured by estimated Glomerular Filtration Rate (eGFR) at 9 months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Renal Artery Stenosis</condition>
  <condition>Hypertension, Renovascular</condition>
  <arm_group>
    <arm_group_label>iCAST RX™ Stent Systen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled subjects will receive the iCAST RX™ Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iCAST™ Rx Stent System</intervention_name>
    <description>All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
    <arm_group_label>iCAST RX™ Stent Systen</arm_group_label>
    <other_name>iCAST™ RX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:

          1. Age ≥ 18 at the time of informed consent.

          2. Subject or subject's legal representative have been informed of the nature of the
             trial, agrees to participate, and has signed an Institutional Review Board
             (IRB)/Ethics Committee (EC) approved Informed Consent Form (ICF).

          3. Subjects that have bilateral kidneys or a solitary functioning kidney with Renal
             Artery Stenosis in at least one kidney and an average Systolic Blood Pressure (SBP) ≥
             155mmHg.

          4. Subject has a history of maximum tolerable dose of ≥ 3 anti-hypertensive medications
             of different classes, one of which must be a diuretic (for at least two weeks prior to
             Medical Documentation Screening period).

             a. A documented history for a minimum of 3 months showing reasonable and aggressive
             efforts to manage hypertension prior to consent. This must include the use of a broad
             variety of medications that have been used and failed or not tolerated.

          5. Subject must have documented clinical evidence to support likelihood of angiographic
             findings &gt; 80% whether it is DUS, CTa, MRa or other medical evidence.

          6. New York Heart Association (NYHA) class I, II, or III the time of trial enrollment.

        Note: When a subject has bilateral Renal Artery Stenosis both of which require stenting, it
        is recommended to treat both kidneys with an iCAST™ RX Stent System during the index
        procedure. In the event that a subject needs a renal stenting procedure staged for renal
        protection, it is important that the Investigator treats the second renal artery with an
        iCAST™ RX Stent System after 30 days of the index procedure. If subjects with bilateral
        stenosis have only one lesion that meets protocol inclusion criteria that lesion should be
        treated per protocol. The recommendation is to NOT treat the second non-qualifying lesion,
        however if the operator feels strongly it is indicated, then they should treat per standard
        of care after 30-days post index procedure in order to comply with exclusion criteria #10.

        Subjects with flash pulmonary edema are allowed into the trial should they meet all other
        Inclusion and Exclusion criteria.

        Angiographic Anatomic Inclusion Criteria:

          1. Angiographic diameter renal artery stenosis ≥ 80% involving unilateral or bilateral
             renal arteries.

             a. The degree of percent diameter stenosis for all lesions intended to be treated,
             must be confirmed via one of the following methods: i. Manual or automated measurement
             with calipers ii. Measured Flow Fraction Reserve (FFR) &lt; 0.8 using a pressure wire
             iii. Measured translesional peak pressure gradient of &gt; 21 mmHg after induced
             hyperemia via dopamine or papaverine using a 4 Fr or less catheter or pressure wire.

             b. Subjects with 60-79% angiographic stenosis who have confirmed FFR &lt; 0.8 may be
             enrolled.

          2. Renal pole-to-pole length &gt; 8cm (per visual estimate).

          3. Target lesion length ≤ 16mm per vessel (per visual estimate).

          4. Renal artery vessel diameter ≥ 5.0mm and ≤ 7.0mm (per visual estimate).

          5. Lesion originating ≤ 15mm of the renal ostium.

        General Exclusion Criteria:

          1. Subject's estimated life expectancy is &lt; 12 months.

          2. Subject has a history of transplanted kidney(s), has had another recent organ
             transplant or polycystic kidney disease.

          3. Subject with estimated glomerular filtration rate (eGFR) ≤ 25 mL/min/1.73 m2

          4. Subject has a history of bleeding diathesis or coagulopathy or refuses blood
             transfusions.

          5. Subject has a known contraindication to heparin, aspirin, thienopyridine, other
             anti-coagulant/antithrombotic therapies, contrast media, stainless steel, and/or
             polytetrafluoroethylene (PTFE).

          6. Subject has had a previous renal bypass operation, a bypass is planned, or the target
             lesion is located within or beyond a bypass graft.

          7. Subject has received a thrombolytic agent within the past 30 days.

          8. Subject has documented acute pulmonary edema or systolic heart failure with ejection
             fraction &lt; 30% and/or hospitalization requiring intubation and ventilation support for
             this diagnosis within the previous 90 days or hypertensive emergencies defined as
             resulting in organ damage.

          9. Concurrent enrollment in any investigational trial wherein subject's participation has
             not been completed.

         10. Subject has had a planned or anticipated cardiovascular surgical or interventional
             procedure outside of the affected renal artery (including, but not limited to, aortic,
             renal, cardiac, carotid, femoro-popliteal, and below the knee) within 30 days prior to
             the index procedure and prior to completion of the 30 day follow-up.

         11. Subject has suffered a stroke or Transient Ischemic Attack (TIA) in the past 3 months.

         12. Subject is pregnant, lactating, or is of child-bearing potential and plans to become
             pregnant during the follow-up trial period.

         13. Subject with significant valvular disease.

         14. Subject with known significant proteinuria &gt; 2+ or &gt; 2.0gm/d.

         15. Subject with known bilateral upper-extremity arterial stenosis that result in
             spuriously low arm pressures or without the ability to gain reliable blood pressure
             measurements in at least one upper extremity.

         16. Subject with active sepsis.

         17. Subject with serum creatinine ≥ 3.0mg/dL.

         18. Subject with NYHA Class IV at the time of enrollment.

         19. Subject is on hemodialysis.

         20. Subject has a history of renal aneurysm.

         21. Subject with cardiogenic shock.

         22. Subject with cardiomyopathy.

         23. Subject has an uncontrolled concurrent illness, including but not limited to ongoing
             or active infection or active autoimmune disease requiring immunosuppressive therapy.

         24. Any subject with clinically significant cardiovascular, respiratory, neurologic,
             hepatic, endocrine, major systematic disease, making implementation or interpretation
             of the protocol or protocol results difficult or who in the opinion of the
             investigator would not be a good candidate for enrollment.

        Angiographic Anatomic Exclusion Criteria:

          1. The planned site of intervention is totally occluded or has an anatomic configuration
             likely to prohibit adequate dilatation, and/or passage or implantation of the
             investigational device.

          2. Subject has multiple ipsilateral lesions of the target renal artery that cannot be
             covered by a single stent.

          3. There is a previously implanted stent in the target vessel or there is a previously
             implanted stent in the contralateral vessel &lt; one year.

          4. Subject has fibromuscular dysplasia, in renal artery and/or other vascular bed.

          5. The target lesion site is associated with a thrombus.

          6. Target lesion treated with laser atherectomy, directional atherectomy or other
             adjuncts to percutaneous balloon angioplasty (PTA).

          7. Subject has a critical stenotic (&gt; 70%) small accessory renal artery.

          8. Subject has an abdominal aortic aneurysm &gt; 4.0cm in diameter or a severe
             atherosclerotic aorta.

          9. Main renal artery length ≤ 15mm precluding the safe deployment of a covered renal
             stent.

         10. Any lesion that would include blocking of renal artery side branch.

         11. Renal artery stenosis due to dissection of renal artery: spontaneous or traumatic.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Rosenfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary Ansel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OhioHealth Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mission Cardiovascular Research Institute</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of the Rockies</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clearwater Cardiovascular and Interventional Consultants</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Health and Hospitals Corporation</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Health Systems</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Carolina Cardiology</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NC Heart and Vascular Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OhioHealth Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont CVA Heart Institute</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennova Healthcare - Turkey Creek Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 23, 2012</study_first_submitted>
  <study_first_submitted_qc>August 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2012</study_first_posted>
  <results_first_submitted>June 27, 2019</results_first_submitted>
  <results_first_submitted_qc>July 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2019</results_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Artery Stenosis</keyword>
  <keyword>Renal Artery Obstruction</keyword>
  <keyword>Renovascular Hypertension</keyword>
  <keyword>Resistant Hypertension</keyword>
  <keyword>Renal Revascularization</keyword>
  <keyword>Atherosclerotic Renal Artery Stenosis</keyword>
  <keyword>Atherosclerotic Renal Artery Stenosis (ARAS)</keyword>
  <keyword>Renal Artery Stenosis (RAS)</keyword>
  <keyword>Uncontrolled hypertension</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Systolic blood pressure</keyword>
  <keyword>Blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Artery Obstruction</mesh_term>
    <mesh_term>Hypertension, Renovascular</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 15, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT01673373/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT01673373/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>iCAST™ RX Stent System</title>
          <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66">Completed primary endpoint follow up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>iCAST™ RX Stent System</title>
          <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.7" spread="10.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Qualifying Lesions</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Unilateral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilateral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.2" spread="12.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Patency</title>
        <description>Primary patency rate at 9 months was defined as continuous patency without the occurrence of a total occlusion of the original lesion, without a re-intervention to treat a partial or total occlusion of the stented segment, or bypass of the stented segment due to clinically-driven restenosis or occlusion.</description>
        <time_frame>9 months</time_frame>
        <population>Subset of enrolled subjects with available duplex ultrasound or angiography assessment within the 9-month visit window.</population>
        <group_list>
          <group group_id="O1">
            <title>iCAST™ RX Stent System</title>
            <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Patency</title>
          <description>Primary patency rate at 9 months was defined as continuous patency without the occurrence of a total occlusion of the original lesion, without a re-intervention to treat a partial or total occlusion of the stented segment, or bypass of the stented segment due to clinically-driven restenosis or occlusion.</description>
          <population>Subset of enrolled subjects with available duplex ultrasound or angiography assessment within the 9-month visit window.</population>
          <units>Subject-lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Subject-lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject-lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The original Performance Goal of 70% patency rate was derived from a thorough literature review of trials with renal bare metal stent placement. Other assumptions included a determination of samples size based upon a one-sided alpha of 0.025 and desired power of 87%, and assumption of 10% attrition. The null hypothesis was that the incidence of primary patency at 9 months is less than or equal to 70%.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Due to the early termination of enrollment, all inferential analyses were interpreted as descriptive and carried out in an exploratory manner.</non_inferiority_desc>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>The p-value was computed using a one-sided exact test of the difference between the observed rate and the Performance Goal (equal to 70%). The defined threshold for statistical significance is .025.</p_value_desc>
            <method>one-sided exact</method>
            <other_analysis_desc>The cumulative incidence of primary patency was computed as the number of subject-lesions with primary patency at 9 months divided by the number of subject-lesions and was analyzed using the allowable window of 243 to 303 trial days.
An exact binomial one-sided 95% CI was constructed and the lower limit compared to the Performance Goal equal to 70%.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure</title>
        <description>Change in systolic blood pressure (SBP) at 9 months as compared to baseline SBP.</description>
        <time_frame>Baseline and 9 months</time_frame>
        <population>Subset of enrolled subjects with available blood pressure data at baseline and 9 months.</population>
        <group_list>
          <group group_id="O1">
            <title>iCAST™ RX Stent System</title>
            <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Change in systolic blood pressure (SBP) at 9 months as compared to baseline SBP.</description>
          <population>Subset of enrolled subjects with available blood pressure data at baseline and 9 months.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="21.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The primary endpoint of systolic blood pressure was analyzed according to the Performance Goal of a decrease in systolic blood pressure of 10 mmHg between procedure and 9 months.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A one-sided 95% Confidence Interval for the mean difference between baseline and 9-month systolic blood pressure was constructed and the lower limit compared to the 10 mmHg performance goal. A p-value of the difference between the estimated systolic blood pressure change from the baseline and the performance goal was computed using a paired t-test.</non_inferiority_desc>
            <p_value>.0192</p_value>
            <p_value_desc>The defined threshold for statistical significance is .025.</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure-Related Major Adverse Events (MAE)</title>
        <description>The occurence of procedure-related MAEs is reported as a percentage of subjects with MAE. Inclusive of:
Procedure- or device-related occurrence of death
Q-Wave myocardial infarction (MI)
Clinically driven target lesion revascularization (TLR)
Significant embolic events defined as unanticipated kidney/bowel infarct, clinically driven by symptoms of abdominal or back pain and confirmed with CT scan or open surgery; lower extremity ulceration or gangrene; or kidney failure.</description>
        <time_frame>30 days, 9 months</time_frame>
        <population>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</population>
        <group_list>
          <group group_id="O1">
            <title>iCAST™ RX Stent System</title>
            <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure-Related Major Adverse Events (MAE)</title>
          <description>The occurence of procedure-related MAEs is reported as a percentage of subjects with MAE. Inclusive of:
Procedure- or device-related occurrence of death
Q-Wave myocardial infarction (MI)
Clinically driven target lesion revascularization (TLR)
Significant embolic events defined as unanticipated kidney/bowel infarct, clinically driven by symptoms of abdominal or back pain and confirmed with CT scan or open surgery; lower extremity ulceration or gangrene; or kidney failure.</description>
          <population>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall subjects experiencing MAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAE within 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAE within 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Technical Success</title>
        <description>Technical success is defined as successful delivery and deployment of the iCAST™ RX Stent System with ≤ 30% residual angiographic stenosis after covered stent deployment (including post-dilatation) assessed via quantitative vascular analysis (QVA) by an independent core laboratory.</description>
        <time_frame>Day of Procedure</time_frame>
        <population>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System. Note that analysis is per subject lesion with available angiography.</population>
        <group_list>
          <group group_id="O1">
            <title>iCAST™ RX Stent System</title>
            <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
          </group>
        </group_list>
        <measure>
          <title>Technical Success</title>
          <description>Technical success is defined as successful delivery and deployment of the iCAST™ RX Stent System with ≤ 30% residual angiographic stenosis after covered stent deployment (including post-dilatation) assessed via quantitative vascular analysis (QVA) by an independent core laboratory.</description>
          <population>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System. Note that analysis is per subject lesion with available angiography.</population>
          <units>Subject-lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Subject-lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject-lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Procedural Success</title>
        <description>Acute procedural success is defined as technical success without the occurrence of MAE prior to hospital discharge.</description>
        <time_frame>Day of Procedure, prior to hospital discharge</time_frame>
        <population>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System. Note that analysis is per subject lesion with available angiography.</population>
        <group_list>
          <group group_id="O1">
            <title>iCAST™ RX Stent System</title>
            <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Procedural Success</title>
          <description>Acute procedural success is defined as technical success without the occurrence of MAE prior to hospital discharge.</description>
          <population>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System. Note that analysis is per subject lesion with available angiography.</population>
          <units>Subject-lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Subject-lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject-lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization (TLR) is measured as the proportion of subjects-lesions that require a clinically-driven reintervention of the target lesion through 9 months.
a. A clinically-driven TLR is defined as a TLR (percutaneous balloon angioplasty (PTA), bare metal stent or repeat covered stent deployment, or surgical bypass) due to documented recurrent hypertension from 30-days post-procedure level and/or deterioration in renal function from baseline value, associated with angiographic core laboratory adjudication of a ≥ 60% diameter covered stent restenosis.</description>
        <time_frame>9 months</time_frame>
        <population>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System. Note that analysis is per subject lesion.</population>
        <group_list>
          <group group_id="O1">
            <title>iCAST™ RX Stent System</title>
            <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization (TLR) is measured as the proportion of subjects-lesions that require a clinically-driven reintervention of the target lesion through 9 months.
a. A clinically-driven TLR is defined as a TLR (percutaneous balloon angioplasty (PTA), bare metal stent or repeat covered stent deployment, or surgical bypass) due to documented recurrent hypertension from 30-days post-procedure level and/or deterioration in renal function from baseline value, associated with angiographic core laboratory adjudication of a ≥ 60% diameter covered stent restenosis.</description>
          <population>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System. Note that analysis is per subject lesion.</population>
          <units>Subject-lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Subject-lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject-lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Incidental TLR</title>
        <description>The rate of incidental TLR is the rate of TLRs not meeting the definition of a clinically-driven TLR.</description>
        <time_frame>9 months</time_frame>
        <population>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System. Note that analysis is per subject lesion.</population>
        <group_list>
          <group group_id="O1">
            <title>iCAST™ RX Stent System</title>
            <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Incidental TLR</title>
          <description>The rate of incidental TLR is the rate of TLRs not meeting the definition of a clinically-driven TLR.</description>
          <population>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System. Note that analysis is per subject lesion.</population>
          <units>Subject-lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Subject-lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject-lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure (SBP) Control</title>
        <description>The change in SBP from baseline to 30 days</description>
        <time_frame>Baseline and 30 days</time_frame>
        <population>Subset of enrolled subjects with available blood pressure measurements at both time points.</population>
        <group_list>
          <group group_id="O1">
            <title>iCAST™ RX Stent System</title>
            <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure (SBP) Control</title>
          <description>The change in SBP from baseline to 30 days</description>
          <population>Subset of enrolled subjects with available blood pressure measurements at both time points.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.6" spread="18.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SBP Control</title>
        <description>The change in SBP from baseline to 9 months</description>
        <time_frame>Baseline and 9 months</time_frame>
        <population>Subset of enrolled subjects with available blood pressure measurements at both time points.</population>
        <group_list>
          <group group_id="O1">
            <title>iCAST™ RX Stent System</title>
            <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
          </group>
        </group_list>
        <measure>
          <title>SBP Control</title>
          <description>The change in SBP from baseline to 9 months</description>
          <population>Subset of enrolled subjects with available blood pressure measurements at both time points.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.7" spread="21.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Patency Rate</title>
        <description>Secondary patency rate at 9 months after a clinically-driven TLR which restores patency after total occlusion.</description>
        <time_frame>9 months</time_frame>
        <population>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System. Note that analysis is per subject lesion.</population>
        <group_list>
          <group group_id="O1">
            <title>iCAST™ RX Stent System</title>
            <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Patency Rate</title>
          <description>Secondary patency rate at 9 months after a clinically-driven TLR which restores patency after total occlusion.</description>
          <population>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System. Note that analysis is per subject lesion.</population>
          <units>Subject-lesions</units>
          <param>Count of Units</param>
          <units_analyzed>Subject-lesions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject-lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Anti-Hypertensive Medications</title>
        <description>Change in number of anti-hypertensive medications as compared to baseline.</description>
        <time_frame>Baseline and 9 months</time_frame>
        <population>Subset of enrolled subjects with available medication information.</population>
        <group_list>
          <group group_id="O1">
            <title>iCAST™ RX Stent System</title>
            <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Anti-Hypertensive Medications</title>
          <description>Change in number of anti-hypertensive medications as compared to baseline.</description>
          <population>Subset of enrolled subjects with available medication information.</population>
          <units>Number of Anti-hypertensive Medications</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Renal Function</title>
        <description>Renal function compared to baseline as measured by estimated Glomerular Filtration Rate (eGFR) at 30 days.</description>
        <time_frame>Baseline and 30 days</time_frame>
        <population>Subset of enrolled subjects with available eGFR measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>iCAST™ RX Stent System</title>
            <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Renal Function</title>
          <description>Renal function compared to baseline as measured by estimated Glomerular Filtration Rate (eGFR) at 30 days.</description>
          <population>Subset of enrolled subjects with available eGFR measurements.</population>
          <units>eGFR mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5520" spread="8.42795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Renal Function</title>
        <description>Renal function compared to baseline as measured by estimated Glomerular Filtration Rate (eGFR) at 9 months.</description>
        <time_frame>Baseline and 9 months</time_frame>
        <population>Subset of enrolled subjects with available eGFR measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>iCAST™ RX Stent System</title>
            <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Renal Function</title>
          <description>Renal function compared to baseline as measured by estimated Glomerular Filtration Rate (eGFR) at 9 months.</description>
          <population>Subset of enrolled subjects with available eGFR measurements.</population>
          <units>eGFR mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9964" spread="13.42781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious Adverse Events were reported through 9 months. Serious Adverse Events were reported through 3 years.</time_frame>
      <desc>Note that the adverse events reported are those reported through the cut off date related to the primary endpoint analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>iCAST™ RX Stent System</title>
          <description>All enrolled subjects, defined as patients that underwent primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Mesenteric artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial restenosis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Brachiocephalic artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Subclavian artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitation of the study was the termination of enrollment due to the change in clinical practice.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sr. Clinical Trial Manager</name_or_title>
      <organization>Getinge</organization>
      <phone>603-864-5219</phone>
      <email>inka.vesela@getinge.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

